Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster
Authors' conclusion
This study showed that the effectiveness of Shingrix in patients with inflammatory arthritis on immunomodulatory treatment was 50%, and the risk of venous thromboembolic events was increased in the 60-90 days after herpes zoster
Study context
- Population
- Patients aged ≥ 18 years with RA, PsA or axSpA, Optum Clinformatics Data Mart
- Participants
- 132,672 patients
- Exposure
- Shingrix vaccination vs no vaccination
- Shingrixn = 28,690
- Outcome
- Incidence of herpes zoster and vaccine effectiveness, calculated as (1 - IRR of herpes zoster) × 100
Methodological detailsobservational
- Observational
Main finding
As reported in the abstract
Herpes zoster incidence rate per 1,000 person-years
Crude vaccine effectiveness
50%
By group
Observational data: associations, not effects.
Further findings
- Received ≥ 1 Shingrix dose
- 21.6% · 28,690
- Received ≥ 1 Shingrix dose — Received a second dose (of those with ≥ 1 dose)
- 73.2%
- Received ≥ 1 Shingrix dose — Second dose within recommended 2-6 months
- 17,598 (83.8%)
Herpes zoster occurrence
- Herpes zoster, all patients
- 4,342 (3.3%)
- Cases after Shingrix vaccination
- 360
Cardiovascular events post-herpes zoster (subgroup with cardiovascular events)
- Risk of VTE elevated in the 60-90 days post-herpes zoster
- No significantly increased risk for any other cardiovascular events
Original publication
Real-world data on the use of the Shingrix vaccine among patients with inflammatory arthritis and risk of cardiovascular events following herpes zoster. Arthritis Res Ther. Published 17 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →